G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
99 hedge funds and large institutions have $664M invested in G1 Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 15 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 20
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
5% more funds holding
Funds holding: 94 → 99 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $863M → $664M (-$199M)
87% less call options, than puts
Call options by funds: $640K | Put options by funds: $5.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.5M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.54M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$8.24M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.55M |
| 5 |
Millennium Management
New York
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.93M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.81M |
| 4 |
JP Morgan Chase
New York
|
-$5.8M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$4.25M |
GTHX Hedge Fund Activity: Q3 2019 in Review
99 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2019, worth a combined $664M — down 23% from $863M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GTHX positions and 15 closed out — a net gain of 6 holders — while 42 added to existing stakes and 20 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $12.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $14.8M sold.
- 99 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2019, up from 94 in Q2 2019.
- Funds reported $664M of G1 Therapeutics, Inc. Common Stock stock for Q3 2019, down 23% quarter-over-quarter.
- 21 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2019 and 15 closed out, a net change of +6 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2019 was T. Rowe Price Associates, an estimated $12.5M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2019 was RA Capital Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2019.